Expanded Access Programs 2018

Expanded Access Programs 2018
March 28-29, 2017 | Washington, DC

CBI’s Expanded Access Programs 2018 focuses on the design, development and practical implementation of early access programs. The summit convenes top industry stakeholders and regulators to examine current approaches in providing investigational, pre-launch or end-of-lifecycle drugs to patients for treatment purposes. A multi-stakeholder faculty will address key issues affecting EAPs and review the potential impact of the evolving legislative landscape.

Visit www.cbinet.com/EAP for more information. Drug Channels subscribers will save $400 off of the standard registration rate when they use discount code CGR664.*

Key Topics to Be Addressed:

• Share best practices and review comparable processes and regulations between U.S. and global expanded access programs
• Streamline policies and procedures to enable the successful launch and sustainability of global EAPs
• Review industry trends in the collection of real-world data in expanded access programs
• Navigate pricing, payment and reimbursement policy for expanded access programs
• Discuss strategies to integrate EAPs into your drug development process at the busiest point of the drug development life cycle
• Understand the clinician’s perspective on single-patient access and group EAPs — Consider barriers to access

This multi-stakeholder event is focused on U.S. and global models for a variety of access management programs, including, but not limited to:

• Expanded Access Programs
• Early Access Programs
• Compassionate Use Programs
• Named Patient Programs and
• Managed Access Programs

Visit www.cbinet.com/EAP for more information. Drug Channels subscribers will save $400 off of the standard registration rate when they use discount code CGR664.*

REGISTER TODAY!

*Applies to standard rates only and may not be combined with other offers, category rates, promotions or applied to an existing registration. Offer not valid on workshop only or academic/non-profit registrations.

---

The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.